EUVIMEDEUVIMED entdecken
Open Access

JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma

Jihyun Kim iD, Jongho Ham iD, Hye Ryun Kang iD, Yong-Soo Bae iD, TaeSoo Kim iD, Hye Young Kim iD

Science Advances · 22.12.2023 · 9 (51)

DOI: 10.1126/sciadv.adi3770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 22.12.2023. Verfasst von Jihyun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Asthma. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steroids are the standard treatment for allergic airway inflammation in asthma, but steroid-refractory asthma poses a challenge. Group 2 innate lymphoid cells (ILC2s), such as T helper 2 (T H 2) cells, produce key asthma-related type 2 cytokines. Recent insights from mouse and human studies indicate a potential connection between ILC2s and steroid-resistant asthma. Here, we highlight that lung ILC2s, rather than T H 2 cells, can develop steroid resistance, allowing them to persist and maintain their disease-driving activity even during steroid treatment. The emergence of multipotent IL-5 + IL-13 + IL-17A + ILC2s is associated with steroid-resistant ILC2s. The Janus kinase 3 (JAK3)/signal transducer and activator of transcription (STAT) 3, 5, and 6 pathways contribute to the acquisition of steroid-resistant ILC2s. The JAK3 inhibitor reduces ILC2 survival, proliferation, and cytokine production in vitro and ameliorates ILC2-driven Alternaria -induced asthma. Furthermore, combining a JAK3 inhibitor with steroids results in the inhibition of steroid-resistant asthma. These findings suggest a potential therapeutic approach for addressing this challenging condition in chronic asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsAsthmaHumansAnimalsMiceImmunity, InnateLymphocytesCytokinesInflammationSteroidsJanus Kinase 3

Substanzen

Janus Kinase InhibitorsCytokinesSteroidsJAK3 protein, humanJanus Kinase 3

Autor:innen und Institutionen

  • Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
  • Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, South Korea.
  • Department of Biological Sciences, SRC Center for Immune Research on Non-lymphoid Organs, Sungkyunkwan University, Suwon, South Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Department of Biological Sciences, Sungkyunkwan University, Suwon, South Korea.
  • Department of Life Science, Multitasking Macrophage Research Center, Ewha Womans University, Seoul, South Korea.

ORCID-Profile: Jihyun Kim, Jongho Ham, Hye Ryun Kang, Yong-Soo Bae, TaeSoo Kim, Hye Young Kim

Zitieren

APA

Kim, J., Ham, J., Kang, H. R., Bae, Y. S., Kim, T., & Kim, H. Y. (2023). JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma. Science Advances, 9(51). https://doi.org/10.1126/sciadv.adi3770

Vancouver

Kim J, Ham J, Kang HR, Bae YS, Kim T, Kim HY. JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma. Science Advances. 2023;9(51). doi:10.1126/sciadv.adi3770

BibTeX
@article{Kim2023,
  author = {Kim, Jihyun and Ham, Jongho and Kang, Hye Ryun and Bae, Yong-Soo and Kim, TaeSoo and Kim, Hye Young},
  title = {JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {51},
  doi = {10.1126/sciadv.adi3770}
}
Kostenlos starten →